Metwali, M., Ali, S., Ahmed, Y., ABD EL GAFFAR, H. (2019). Level of CA125 in Gynaecologic Masses Necessitating Operative Intervention Prospective cohort study. test, 23(2), 117-122. doi: 10.21608/smj.2019.47652
Mohamed Metwali; Salah Ali; Yasser Ahmed; HAZEM MOHAMMED ABD EL GAFFAR. "Level of CA125 in Gynaecologic Masses Necessitating Operative Intervention Prospective cohort study". test, 23, 2, 2019, 117-122. doi: 10.21608/smj.2019.47652
Metwali, M., Ali, S., Ahmed, Y., ABD EL GAFFAR, H. (2019). 'Level of CA125 in Gynaecologic Masses Necessitating Operative Intervention Prospective cohort study', test, 23(2), pp. 117-122. doi: 10.21608/smj.2019.47652
Metwali, M., Ali, S., Ahmed, Y., ABD EL GAFFAR, H. Level of CA125 in Gynaecologic Masses Necessitating Operative Intervention Prospective cohort study. test, 2019; 23(2): 117-122. doi: 10.21608/smj.2019.47652

Level of CA125 in Gynaecologic Masses Necessitating Operative Intervention Prospective cohort study

Sohag Medical Journal
Article 24, Volume 23, Issue 2, April 2019, Pages 117-122    PDF (438.04 K)
Document Type: Original Article
DOI: 10.21608/smj.2019.47652
Authors
Mohamed Metwali; Salah Ali; Yasser Ahmed; HAZEM MOHAMMED ABD EL GAFFAR
Department of Obstetrics and Gynecology, Faculty of Medicine, Sohag University, Egypt.
Abstract
Objective: to determine :

The different types of gynecologic pelvic or pelvic abdominal masses necessitating surgical intervention associated with increased CA125 levels.
The relation between initial level of CA125 and histopathological nature of the mass.
In malignant cases: relation between preoperative CA125 level and stage of the tumor.
After surgery: whether decline in increased CA125 level occurs 6 months after surgery or not.

Methods: The study was conducted during a period from April 2017 to April 2018.
. IBM-SPSS ( version 24) was used for statistical data analysis.
Results: The mean age of the study group was 44±11 years, with a range of 17-67 years.The most common surgical problem of our study group was myoma, present in 22 cases (37.3%). This was followed by simple serous cyst and endometrial carcinoma (8 cases each, 13.6%), then endometriotic cyst and mature cystic teratoma (6 cases each, 10.2%), then ovarian fibroma, ovarian cancer and endometrial hyperplasia (5 cases each, 8.5%), adenomyosis (3 cases, 5.1%) and lastly mucinous cystadenoma (one case, 1.7%).The mean CA125 of our study group had a mean of 38.6 U/ml, with a very high standard deviation of over 59 U/ml; reflected in the very wide range from 4.5 up to 446 U/ml.The highest mean level of CA125 was seen among patients with ovarian cancer (160.6 U/ml). This was followed by ovarian fibroma (57.5 U/ml), then adenomyosis (42.7 U/ml), endometriotic cyst (42.6 U/ml), simple serous cyst (22.2 U/ml), mucinous cystadenoma (22 U/ml), myoma (21.9 U/ml), endometrial carcinoma (20.2 U/ml) and lastly endometrial hyperplasia (17.6 U/ml).CA 125 level was normal in all cases of myoma, dermoid cyst, simple serous cyst, mucinous cystadenoma, endometrial hyperplasia, and endometrial carcinoma.CA125 elevated in all cases of ovarian cancer, endometriotic cyst, adenomyosis and elevated in 60% in cases of ovarian fibroma. Most cases of ovarian cancer (80%) had marked elevation in CA125 level (level >100 U/ml ) and the increase in CA125 level was more marked with increase staging of the cancer , all cases of endometriotic cyst had mild to moderate elevation in CA125 level which were > 100 U/ml , all cases of adenomyosis had mild elevation in CA125level which not more than     50 U/ ml, in cases of ovarian fibroma CA125 level were normal in about 40% of the cases and elevated in about 60% of the cases (40% had moderate elevation in CA125 level which was> 100 U/ml and 20% had marked elevation with CA125 level < 100 U/ml .).There was proportional relationship between CA125 level and ovarian cancer stage, mean CA125 level in stage I was 85.8 U/ml versus 372.3 U/ml in stage II ( P < 0.001).All cases of endometrial cancer early diagnosed in stage I had normal CA125 level (10.6 – 28.3 U/ml).All cases with preoperative elevated CA125 level, the level returned to the normal when repeated 6 months postoperatively, cases of ovarian cancer, CA125 level returned to the normal after receiving six cycles of chemotherapy postoperatively.
Conclusion: CA125 is a simple and good screening test and should be routinely recommended for all cases of pelvic or pelvic abdominal masses before operative intervention, It helps to guess the diagnosis of ovarian cancer cases (it's level mostly >100 U/ml). It helps in the differential diagnosis between endometriotic cysts (elevated CA125 level ) and hemorrhagic ovarian and dermoid cysts (normal CA125 level ).It also helps in the differential diagnosis between uterine fibroids and adenomyosis being elevated in the latter.CA125 serum level can suggest the stage of ovarian cancer. In cases with elevated preoperative CA125 levels, it is expected that this level will normalize within 6 months postoperatively.
 
References
  1. Benjapibal M, Neungton C (2007): Pre-Operative Prediction of Serum CA125 Level in Women with Ovarian Masses J Med Assoc Thai; 90 (10): 1986-91.
  2.  Crawford SM, Peace J. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol. 2005;16:47–50.
  3.  Dawood MY, Khan-Dawood FS. Plasma insulin-like growth factor-I, CA 125, estrogen, and progesterone in women with leiomyomas. Fertil Steril. 1994;61:617–621.
  4.  Dingiloglu BS, Gungor T, Ozdal B, Cavkaytar S, Bilge U, Mollamahmutoglu L. Serum leptin levels in women with uterine leiomyomas. Taiwan J Obstet Gynecol. 2007;46:33–37.
  5. Di-Xia C, Schwartz PE, Xinguo L, Zhan Y. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol 1988;72:23-7.
  6. Dotters DJ. Preoperative CA 125 in endometrial cancer: is it useful? Am J Obstet Gynecol 2000;182:1328–34.
  7. Duraisamy S, Ramasamy S, Kharbanda S, Kufe D (2006): "Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4, AND MUC16". Gene. 373: 28–34.
  8. Gniewek P, Kolinski A (2012): "Coarse-grained modeling of mucus barrier properties". Biophysical Journal. 102 (2): 195–200.
  9. Kauppila A, Telimaa S, Ronnberg L, Vuori J. Placebo-controlled study on serum concentrations of CA-125 before and after treatment of endometriosis with danazol or high-dose medroxyprogesterone acetate alone or after surgery. Fertil Steril 1988;49:37-41.
  10. Schmidt C (2011): "CA-125: a biomarker put to the test". Journal of the National Cancer Institute. 103 (17): 1290–1.
  11. Takahashi K, Kijima S, Yoshino K, Shibukawa T, Moriyama M, Iwanari O, Sawada K, Matsunaga I, Murao F, Kitao M. [Differential diagnosis between leiomyomata uteri and adenomyosis using CA 125 as a new tumor marker of ovarian carcinoma] . Nihon Sanka Fujinka Gakkai Zasshi. 1985;37:591–595. 
  12. Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, Timmerman D, De Moor B, Vergote E (2011): HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. British Journal of Cancer 104, 863 – 870.
  13. Yen, P.; Khong, K.; Lamba, R.; Corwin, M. T.; Gerscovich, E. O. (2013). "Ovarian fibromas and fibrosarcomas: Sonographic correlation with computed tomography and magnetic resonance imaging: A 5-year single-institution experience". Journal of ultrasound in medicine. 32 (1): 13–18. PMID 23269706.
  14. Yin BW, Dnistrian A, Lloyd KO (2002): "Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene". International Journal of Cancer. 98 (5): 737–40.
  15. Zhou Y, Wu B, Li H. [The value of serum CA 125 assays in the diagnosis of uterine adenomyosis]. Zhonghua Fu Chan Ke Za Zhi. 1996;31:590–593. 
 

 

 

 

Statistics
Article View: 433
PDF Download: 655